• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫疗法诱导的重叠综合征：肌炎、重症肌无力和心肌炎——病例系列

Immunotherapy-Induced Overlap Syndrome: Myositis, Myasthenia Gravis, and Myocarditis-A Case Series.

作者信息

Aggarwal Nikhil, Bianchini Diletta, Parkar Rosemeen, Turner Jennifer

机构信息

Kent Oncology Centre, Maidstone General Hospital, Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, UK.

出版信息

Case Rep Med. 2024 Mar 29;2024:5399073. doi: 10.1155/2024/5399073. eCollection 2024.

DOI:10.1155/2024/5399073
PMID:38585685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10997416/
Abstract

Immune checkpoint inhibitors (ICI) are monoclonal antibodies that target immune checkpoint inhibitory receptors. They have revolutionised cancer treatment but can be associated with a wide range of adverse side effects. Rarely, they can be associated with the triad of myositis, myasthenia gravis, and myocarditis or overlap syndrome. Prompt recognition and early intervention are needed to treat these potentially life-threatening conditions. We report a case series of patients with ICI-related overlap syndrome, including the first with avelumab, and discuss the current management guidelines.

摘要

免疫检查点抑制剂（ICI）是靶向免疫检查点抑制性受体的单克隆抗体。它们彻底改变了癌症治疗方式，但可能会伴有多种不良副作用。罕见情况下，它们可能与肌炎、重症肌无力和心肌炎三联征或重叠综合征相关。需要迅速识别并尽早干预以治疗这些可能危及生命的病症。我们报告了一系列免疫检查点抑制剂相关重叠综合征患者的病例，包括首例使用阿维鲁单抗的患者，并讨论了当前的管理指南。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f380/10997416/ae909a0c45ef/CRIM2024-5399073.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f380/10997416/ae909a0c45ef/CRIM2024-5399073.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f380/10997416/ae909a0c45ef/CRIM2024-5399073.001.jpg

相似文献

1
Immunotherapy-Induced Overlap Syndrome: Myositis, Myasthenia Gravis, and Myocarditis-A Case Series.免疫疗法诱导的重叠综合征：肌炎、重症肌无力和心肌炎——病例系列
Case Rep Med. 2024 Mar 29;2024:5399073. doi: 10.1155/2024/5399073. eCollection 2024.
2
Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.免疫检查点抑制剂相关性心肌炎合并肌炎/重症肌无力重叠综合征：病例系统综述。
Oncologist. 2021 Dec;26(12):1052-1061. doi: 10.1002/onco.13931. Epub 2021 Aug 25.
3
Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review.免疫检查点抑制剂相关心肌炎、肌炎、重症肌无力和肝酶异常：病例系列研究及综述。
Immunotherapy. 2022 May;14(7):511-520. doi: 10.2217/imt-2021-0225. Epub 2022 Mar 24.
4
Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.免疫检查点抑制剂相关重症肌无力、肌炎和心肌炎重叠综合征。
Am J Emerg Med. 2021 Aug;46:51-55. doi: 10.1016/j.ajem.2021.03.005. Epub 2021 Mar 8.
5
Management of respiratory failure in immune checkpoint inhibitors-induced overlap syndrome: a case series and review of the literature.免疫检查点抑制剂相关重叠综合征所致呼吸衰竭的管理：病例系列及文献复习。
BMC Anesthesiol. 2023 Sep 12;23(1):310. doi: 10.1186/s12871-023-02257-z.
6
Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature.免疫检查点抑制剂诱发的心肌炎与肌炎/重症肌无力重叠综合征继发食管裂孔疝：一例病例报告及文献复习
Front Med (Lausanne). 2022 Nov 15;9:950801. doi: 10.3389/fmed.2022.950801. eCollection 2022.
7
Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.免疫检查点抑制剂诱导的重症肌无力、心肌炎和肌炎患者早期免疫抑制治疗可改善预后：病例系列研究。
Support Care Cancer. 2023 Aug 12;31(9):518. doi: 10.1007/s00520-023-07987-x.
8
Myocarditis, Myositis, and Myasthenia Gravis Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A Systematic Review.与免疫检查点抑制剂相关的心肌炎、肌炎和重症肌无力重叠综合征：一项系统综述
Diagnostics (Basel). 2024 Aug 16;14(16):1794. doi: 10.3390/diagnostics14161794.
9
Checkpoint inhibitor-related myasthenia-myocarditis-myositis overlap syndrome in the orbit.眼眶中与检查点抑制剂相关的重症肌无力-心肌炎-肌炎重叠综合征
Orbit. 2025 Apr;44(2):200-206. doi: 10.1080/01676830.2024.2351519. Epub 2024 May 26.
10
Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment.重症肌无力、肌炎和心肌炎：免疫检查点抑制剂治疗相关免疫不良反应的致命三联征。
BMJ Case Rep. 2022 Dec 8;15(12):e251966. doi: 10.1136/bcr-2022-251966.

引用本文的文献

1
Immunotherapy-Induced Cardiotoxicity: A Narrative Review of Real-World Case Reports, Recent Information and Clinical Evidence.免疫疗法诱发的心脏毒性：真实世界病例报告、最新信息及临床证据的叙述性综述
Cardiovasc Toxicol. 2025 Jul 13. doi: 10.1007/s12012-025-10038-y.
2
Management of Triple M Syndrome: A Narrative Review of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis, Myositis and Myocarditis.三 M 综合征的管理：免疫检查点抑制剂诱发的重症肌无力、肌炎和心肌炎的叙述性综述
Cancers (Basel). 2025 Jun 20;17(13):2063. doi: 10.3390/cancers17132063.
3
The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis.

本文引用的文献

1
Triple M Syndrome: Implications for Hematology-Oncology Advanced Practice Providers.三重 M 综合征：对血液肿瘤学高级实践提供者的影响。
Clin J Oncol Nurs. 2023 Sep 15;27(5):463-467. doi: 10.1188/23.CJON.463-467.
2
Risk Factors for Immune Checkpoint Inhibitor-Mediated Cardiovascular Toxicities.免疫检查点抑制剂相关心血管毒性的危险因素。
Curr Oncol Rep. 2023 Jul;25(7):753-763. doi: 10.1007/s11912-023-01414-4. Epub 2023 Apr 20.
3
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
基于FAERS数据库和文献计量分析的托法替布在鼻咽癌中的不良事件。 （注：原文药物名称有误，正确的是“toripalimab”译为“托瑞帕利单抗” ，这里按照你提供的错误名称翻译了，实际应用中请使用正确名称）
PLoS One. 2025 Jun 20;20(6):e0326216. doi: 10.1371/journal.pone.0326216. eCollection 2025.
4
Pembrolizumab-induced myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS) treated with Efgartigimod: case report.用艾加莫德治疗的帕博利珠单抗诱导的心肌炎、肌炎和重症肌无力重叠综合征（IM3OS）：病例报告
Immunotherapy. 2025 Jun;17(8):561-566. doi: 10.1080/1750743X.2025.2517522. Epub 2025 Jun 13.
5
Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review.免疫相关的心肌炎、肌炎和重症肌无力（MMM）重叠综合征的管理：一项单机构病例系列研究及文献综述
Front Immunol. 2025 May 8;16:1597259. doi: 10.3389/fimmu.2025.1597259. eCollection 2025.
6
Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review.免疫检查点抑制剂诱发的类固醇难治性心肌炎对英夫利昔单抗治疗有效：两例病例报告及文献复习。
Cardiovasc Toxicol. 2024 Nov;24(11):1174-1191. doi: 10.1007/s12012-024-09918-6. Epub 2024 Sep 10.
7
Myocarditis, Myositis, and Myasthenia Gravis Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A Systematic Review.与免疫检查点抑制剂相关的心肌炎、肌炎和重症肌无力重叠综合征：一项系统综述
Diagnostics (Basel). 2024 Aug 16;14(16):1794. doi: 10.3390/diagnostics14161794.
8
Durvalumab-Induced Triple-M Syndrome.度伐利尤单抗诱导的三联征综合征。
Eur J Case Rep Intern Med. 2024 Jul 30;11(8):004729. doi: 10.12890/2024_004729. eCollection 2024.
9
Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database.PD-1、PD-L1、CTLA-4和LAG-3免疫检查点抑制剂的不良事件：对美国食品药品监督管理局不良事件数据库的分析
Antibodies (Basel). 2024 Jul 17;13(3):59. doi: 10.3390/antib13030059.
10
Generation and Accumulation of Various Advanced Glycation End-Products in Cardiomyocytes May Induce Cardiovascular Disease.心肌细胞中各种晚期糖基化终产物的产生和积累可能导致心血管疾病。
Int J Mol Sci. 2024 Jul 3;25(13):7319. doi: 10.3390/ijms25137319.
免疫疗法毒性的管理：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2022 Dec;33(12):1217-1238. doi: 10.1016/j.annonc.2022.10.001. Epub 2022 Oct 18.
4
Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit.免疫检查点抑制剂诱导的伴重症肌无力样误导性表现的肌炎/心肌炎：重症监护病房的病例系列
J Clin Med. 2022 Sep 23;11(19):5611. doi: 10.3390/jcm11195611.
5
Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy.接受免疫治疗的癌症患者中与免疫相关的罕见不良事件
Diagnostics (Basel). 2022 Aug 29;12(9):2091. doi: 10.3390/diagnostics12092091.
6
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：ASCO 指南更新。
J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1.
7
Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.免疫检查点抑制剂相关性心肌炎合并肌炎/重症肌无力重叠综合征：病例系统综述。
Oncologist. 2021 Dec;26(12):1052-1061. doi: 10.1002/onco.13931. Epub 2021 Aug 25.
8
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis.免疫检查点抑制剂诱发的重症肌无力
Front Neurol. 2020 Jul 16;11:634. doi: 10.3389/fneur.2020.00634. eCollection 2020.
9
The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma.免疫检查点抑制剂的“可怕三联征”：西米普利单抗诱发转移性皮肤鳞状细胞癌患者重症肌无力、心肌炎和肌炎的病例报告
Case Reports Immunol. 2020 Jul 4;2020:5126717. doi: 10.1155/2020/5126717. eCollection 2020.
10
Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment.免疫检查点抑制剂相关性心肌炎：病理生理特征、诊断与治疗
J Am Heart Assoc. 2020 Jan 21;9(2):e013757. doi: 10.1161/JAHA.119.013757.